Clinical Trial Update: Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on safety, pharmacokinetics, and efficacy of dupilumab in children 6 months to under 6 years with moderate-to-severe atopic dermatitis (Li…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Dermatitis, Atopic | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2022-07-28